These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors. Sun S; Zhang J; Wang N; Kong X; Fu F; Wang H; Yao J Molecules; 2017 Dec; 23(1):. PubMed ID: 29295519 [TBL] [Abstract][Full Text] [Related]
8. Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study. El Hamaky NFM; Hamdi A; Bayoumi WA; Elgazar AA; Nasr MNA Bioorg Chem; 2024 Jul; 148():107437. PubMed ID: 38749114 [TBL] [Abstract][Full Text] [Related]
9. Discovery of highly potent and selective EGFR Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818 [TBL] [Abstract][Full Text] [Related]
10. Discovery of novel thiazole derivatives containing pyrazole scaffold as PPAR-γ Agonists, α-Glucosidase, α-Amylase and COX-2 inhibitors; Design, synthesis and in silico study. Fadaly WAA; Elshewy A; Nemr MTM; Abdou K; Sayed AM; Kahk NM Bioorg Chem; 2024 Nov; 152():107760. PubMed ID: 39197383 [TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers. Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M). Shaheen MA; El-Emam AA; El-Gohary NS Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080 [TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme. El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967 [TBL] [Abstract][Full Text] [Related]
18. Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors. Zhou F; Zhang L; Jin Y; Liu W; Cheng P; He X; Xie J; Shen S; Lei J; Ji H; Hu Y; Liu Y; Cui Y; Lv Q; Lan J Bioorg Med Chem Lett; 2018 Apr; 28(7):1257-1261. PubMed ID: 29534926 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR Ding S; Dong X; Gao Z; Zheng X; Ji J; Zhang M; Liu F; Wu S; Li M; Song W; Shen J; Duan W; Liu J; Chen Y Bioorg Chem; 2022 Jan; 118():105471. PubMed ID: 34798457 [TBL] [Abstract][Full Text] [Related]
20. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFR Raghunath Khedkar N; Sindkhedkar M; Joseph A Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]